Humanigen, Inc. (HGENQ) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
830 MORRIS TURNPIKE SHORT HILLS, NJ 07078 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 10,155 | 24,725 | 47,046 | 68,948 | 70,016 | 76,500 | |||
| Cash and cash equivalent | 10,155 | 24,725 | 47,046 | 68,948 | 70,016 | 76,500 | |||
| Other undisclosed current assets | 950 | 1,153 | 2,313 | 2,287 | 955 | 1,347 | |||
| Total current assets: | 11,105 | 25,878 | 49,359 | 71,235 | 70,971 | 77,847 | |||
| Noncurrent Assets | |||||||||
| Other noncurrent assets | 90 | 90 | 90 | 90 | 90 | 90 | |||
| Total noncurrent assets: | 90 | 90 | 90 | 90 | 90 | 90 | |||
| TOTAL ASSETS: | 11,195 | 25,968 | 49,449 | 71,325 | 71,061 | 77,937 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 55,311 | 75,503 | 71,060 | 67,054 | 64,580 | 64,564 | |||
| Accounts payable | 40,520 | 53,340 | 56,665 | 47,873 | 44,698 | 45,962 | |||
| Accrued liabilities | 14,791 | 22,163 | 14,395 | 19,181 | 19,882 | 18,602 | |||
| Deferred revenue | 883 | 884 | 3,091 | 4,127 | 4,145 | 4,145 | |||
| Debt | 2,839 | ||||||||
| Total current liabilities: | 56,194 | 76,387 | 76,990 | 71,181 | 68,725 | 68,709 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 22,547 | 25,193 | 25,006 | 24,818 | |||||
| Long-term debt, excluding current maturities | 22,547 | 25,193 | 25,006 | 24,818 | |||||
| Liabilities, other than long-term debt | 1,766 | 1,986 | 1,018 | 2,054 | |||||
| Deferred revenue | 1,766 | 1,986 | 1,018 | 2,054 | |||||
| Total noncurrent liabilities: | 1,766 | 1,986 | 22,547 | 25,193 | 26,024 | 26,872 | |||
| Total liabilities: | 57,960 | 78,373 | 99,537 | 96,374 | 94,749 | 95,581 | |||
| Equity | |||||||||
| Equity, attributable to parent | (46,765) | (52,405) | (50,088) | (25,049) | (23,688) | (17,644) | |||
| Common stock | 119 | 119 | 71 | 70 | 64 | 60 | |||
| Additional paid in capital | 634,925 | 633,675 | 612,347 | 607,238 | 587,327 | 559,835 | |||
| Accumulated deficit | (681,809) | (686,199) | (662,506) | (632,357) | (611,079) | (577,539) | |||
| Total equity: | (46,765) | (52,405) | (50,088) | (25,049) | (23,688) | (17,644) | |||
| TOTAL LIABILITIES AND EQUITY: | 11,195 | 25,968 | 49,449 | 71,325 | 71,061 | 77,937 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 221 | 221 | 1,036 | 1,036 | 1,037 | 1,036 | ||
| Gross profit: | 221 | 221 | 1,036 | 1,036 | 1,037 | 1,036 | ||
| Operating expenses | 4,076 | (22,942) | (30,387) | (21,565) | (33,382) | (67,015) | ||
| Operating income (loss): | 4,297 | (22,721) | (29,351) | (20,529) | (32,345) | (65,979) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 211 | 326 | (30) | (15) | (447) | (9) | ||
| Interest and debt expense | (118) | (1,298) | (768) | (734) | (748) | (751) | ||
| Income (loss) from continuing operations: | 4,390 | (23,693) | (30,149) | (21,278) | (33,540) | (66,739) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (23,693) | (30,149) | (21,278) | (33,540) | (66,739) | |
| Net income (loss) available to common stockholders, diluted: | 4,390 | (23,693) | (30,149) | (21,278) | (33,540) | (66,739) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 4,390 | (23,693) | (30,149) | (21,278) | (33,540) | (66,739) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 4,390 | (23,693) | (30,149) | (21,278) | (33,540) | (66,739) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.